Bank of Montreal’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-227
| Closed | -$6K | – | 3973 |
|
|
2021
Q2 | $6K | Sell |
227
-5,208
| -96% | -$127K | ﹤0.01% | 3584 |
|
|
2021
Q1 | $145K | Buy |
5,435
+187
| +4% | +$6.48K | ﹤0.01% | 3237 |
|
|
2020
Q4 | $177K | Hold |
5,248
| – | – | ﹤0.01% | 3291 |
|
|
2020
Q3 | $52K | Sell |
5,248
-14
| -0.3% | -$363 | ﹤0.01% | 3412 |
|
|
2020
Q2 | $184K | Hold |
5,262
| – | – | ﹤0.01% | 2775 |
|
|
2020
Q1 | $88K | Hold |
5,262
| – | – | ﹤0.01% | 2649 |
|
|
2019
Q4 | $619K | Sell |
5,262
-15
| -0.3% | -$1.48K | ﹤0.01% | 2545 |
|
|
2019
Q3 | $479K | Hold |
5,277
| – | – | ﹤0.01% | 2441 |
|
|
2019
Q2 | $289K | Buy |
5,277
+104
| +2% | +$4.57K | ﹤0.01% | 2733 |
|
|
2019
Q1 | $253K | Buy |
5,173
+14
| +0.3% | +$691 | ﹤0.01% | 2619 |
|
|
2018
Q4 | $206K | Buy |
5,159
+1,942
| +60% | +$84.7K | ﹤0.01% | 2561 |
|
|
2018
Q3 | $199K | Hold |
3,217
| – | – | ﹤0.01% | 2755 |
|
|
2018
Q2 | $88K | Hold |
3,217
| – | – | ﹤0.01% | 3187 |
|
|
2018
Q1 | $157K | Buy |
3,217
+3,213
| +80,325% | +$159K | ﹤0.01% | 2744 |
|
|
2017
Q4 | $0 | Sell |
4
-3,642
| -100% | -$245K | ﹤0.01% | 4355 |
|
|
2017
Q3 | $248K | Hold |
3,646
| – | – | ﹤0.01% | 2576 |
|
|
2017
Q2 | $231K | Hold |
3,646
| – | – | ﹤0.01% | 2596 |
|
|
2017
Q1 | $238K | Hold |
3,646
| – | – | ﹤0.01% | 2384 |
|
|
2016
Q4 | $245K | Sell |
3,646
-50
| -1% | -$3.36K | ﹤0.01% | 2407 |
|
|
2016
Q3 | $317K | Hold |
3,696
| – | – | ﹤0.01% | 2265 |
|
|
2016
Q2 | $245K | Sell |
3,696
-557
| -13% | -$37.8K | ﹤0.01% | 2377 |
|
|
2016
Q1 | $311K | Sell |
4,253
-132
| -3% | -$10.3K | ﹤0.01% | 2245 |
|
|
2015
Q4 | $537K | Buy |
4,385
+3,454
| +371% | +$407K | ﹤0.01% | 1961 |
|
|
2015
Q3 | $120K | Sell |
931
-773
| -45% | -$130K | ﹤0.01% | 2527 |
|
|
2015
Q2 | $258K | Sell |
1,704
-217
| -11% | -$40.3K | ﹤0.01% | 2292 |
|
|
2015
Q1 | $442K | Sell |
1,921
-394
| -17% | -$92.7K | ﹤0.01% | 2009 |
|
|
2014
Q4 | $556K | Buy |
2,315
+250
| +12% | +$61.5K | ﹤0.01% | 2011 |
|
|
2014
Q3 | $763K | Buy |
2,065
+66
| +3% | +$31K | ﹤0.01% | 1891 |
|
|
2014
Q2 | $978K | Sell |
1,999
-42
| -2% | -$20.1K | ﹤0.01% | 1760 |
|
|
2014
Q1 | $1.13M | Buy |
2,041
+88
| +5% | +$53.6K | ﹤0.01% | 1599 |
|
|
2013
Q4 | $1.17M | Buy |
1,953
+1,354
| +226% | +$1.11M | ﹤0.01% | 1409 |
|
|
2013
Q3 | $681K | Buy |
+599
| New | +$891K | ﹤0.01% | 1640 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 3671 |
|
Other funds holding GRCE
VF
TSS
EDRH
SIAP
Bank of Montreal's GRCE Position: Q3 2021 in Review
Bank of Montreal sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 227 shares — an estimated $6K sold.
Bank of Montreal first reported a position in GRCE in Q3 2013 and held it in 32 quarters. The position peaked at $1.17M in Q4 2013. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.
- Bank of Montreal reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
- Bank of Montreal sold 227 Grace Therapeutics shares in Q3 2021, an estimated $6K.
- Bank of Montreal first reported a position in Grace Therapeutics in Q3 2013 and held it in 32 quarters.
- Bank of Montreal's Grace Therapeutics position peaked at $1.17M in Q4 2013.
- 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.
Based on Bank of Montreal's 13F filing for Q3 2021, filed 12 Nov 2021.